SAN FRANCISCO — In patients with suspected myocardial infarction (MI) with nonobstructive coronary lesions, an intensive approach to diagnosis and subsequent tailored treatment based on the underlying ...

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...

What exactly is optimal medical therapy (OMT) for angina relief? And how long should doctors prescribe it before proceeding to an invasive approach in symptomatic patients with stable ischemic heart ...

Please provide your email address to receive an email when new articles are posted on . Compared with CT coronary angiography alone, coronary function testing improved endotype diagnosis for angina ...

Please provide your email address to receive an email when new articles are posted on . In patients with heart attack without blocked arteries, a stratified treatment ...

VANCOUVER, Dec. 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement ...

DUBLIN, Sept. 1, 2020 /PRNewswire/ -- The "Refractory Angina - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report ...